Dynamics of complement activation in aHUS and how to monitor eculizumab therapy

Atypical hemolytic-uremic syndrome (aHUS) is associated with genetic complement abnormalities/anti–complement factor H antibodies, which paved the way to treatment with eculizumab. We studied 44 aHUS patients and their relatives to (1) test new assays of complement activation, (2) verify whether suc...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Noris, Marina, Galbusera, Miriam, Gastoldi, Sara, Macor, Paolo, Banterla, Federica, Bresin, Elena, Tripodo, Claudio, Bettoni, Serena, Donadelli, Roberta, Valoti, Elisabetta, Tedesco, Francesco, Amore, Alessandro, Coppo, Rosanna, Ruggenenti, Piero, Gotti, Eliana, Remuzzi, Giuseppe
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2014
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4162105/
https://ncbi.nlm.nih.gov/pubmed/25037630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-02-558296
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares